NCT05787535 2024-02-02
HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor
HRYZ Biotech Co.
Phase 1 Unknown
Clinical Trials
21 trialsNCT05732948 2023-11-29
PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Unknown
NCT03600649 2023-11-21
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
Salarius Pharmaceuticals, LLC
Phase 1 Unknown
NCT04825496 2023-09-21
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Unknown
NCT05266196 2023-08-01
A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
Salarius Pharmaceuticals, LLC
Phase 1/2 Unknown
NCT05727683 2023-02-14
CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic Leukemia
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 1 Unknown
NCT03692663 2022-08-01
Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT05122221 2022-06-28
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
Corregene Biotechnology Co., Ltd
Phase 1 Unknown
NCT05155215 2021-12-13
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Unknown
NCT03943472 2021-08-31
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
Hrain Biotechnology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT02785250 2021-06-18
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 1/2 Unknown
NCT04653493 2021-03-19
CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Sabz Biomedicals
Phase 1 Unknown
NCT03294577 2021-01-15
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
BeyondSpring Pharmaceuticals Inc.
Phase 3 Unknown
NCT04626726 2020-11-13
Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04626752 2020-11-13
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT04626765 2020-11-13
CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia
Hebei Senlang Biotechnology Inc., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03778619 2020-07-28
MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin
GC Cell Corporation
Phase 1/2 Unknown
NCT03528421 2018-07-16
Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown
NCT03344705 2017-11-17
Safety and Efficacy Evaluation of IM19 Cells
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown
NCT01304797 2017-01-06
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Merrimack Pharmaceuticals
Phase 1 Unknown
NCT01947062 2013-09-20
Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma
Swami Rama Cancer Hospital and Research Institute
Phase 3 Unknown